EA202092206A1 - Производные дигидрохромена - Google Patents

Производные дигидрохромена

Info

Publication number
EA202092206A1
EA202092206A1 EA202092206A EA202092206A EA202092206A1 EA 202092206 A1 EA202092206 A1 EA 202092206A1 EA 202092206 A EA202092206 A EA 202092206A EA 202092206 A EA202092206 A EA 202092206A EA 202092206 A1 EA202092206 A1 EA 202092206A1
Authority
EA
Eurasian Patent Office
Prior art keywords
represent
hydrogen atom
dihydrochromene
derivatives
atom
Prior art date
Application number
EA202092206A
Other languages
English (en)
Inventor
Хитоси Бан
Сейдзи Камиока
Юсуке Саваяма
Мики Хасизуме
Original Assignee
Сумитомо Дайниппон Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сумитомо Дайниппон Фарма Ко., Лтд. filed Critical Сумитомо Дайниппон Фарма Ко., Лтд.
Publication of EA202092206A1 publication Critical patent/EA202092206A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Изобретение относится к соединению формулы (I), где R1A, R1B, R1C и R1D представляют собой атом водорода и т.д., R2A и R2B представляют собой атом водорода и т.д., R3A, R3B, R3C и R3D представляют собой атом водорода и т.д., L представляет собой связь и т.д., V представляет собой C1-6алкилен, Q представляет собой необязательно замещенный имидазол, или его фармацевтически приемлемую соль в качестве нового противоопухолевого агента, нацеленного на CSC, которые, как считается, принимают непосредственное участие в непрекращающемся разрастании злокачественной опухоли, метастазировании или рецидиве рака и устойчивости к противоопухолевым агентам.
EA202092206A 2018-03-20 2019-03-19 Производные дигидрохромена EA202092206A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018052971 2018-03-20
PCT/JP2019/011439 WO2019181939A1 (ja) 2018-03-20 2019-03-19 ジヒドロクロメン誘導体

Publications (1)

Publication Number Publication Date
EA202092206A1 true EA202092206A1 (ru) 2020-12-15

Family

ID=67986459

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092206A EA202092206A1 (ru) 2018-03-20 2019-03-19 Производные дигидрохромена

Country Status (21)

Country Link
US (3) US10807993B2 (ru)
EP (1) EP3770162B1 (ru)
JP (2) JP6733072B2 (ru)
KR (1) KR20200135401A (ru)
CN (1) CN111886237A (ru)
AU (1) AU2019239481B2 (ru)
BR (1) BR112020017481A8 (ru)
CA (1) CA3092255A1 (ru)
CY (1) CY1126034T1 (ru)
DK (1) DK3770162T3 (ru)
EA (1) EA202092206A1 (ru)
ES (1) ES2941771T3 (ru)
FI (1) FI3770162T3 (ru)
HU (1) HUE062256T2 (ru)
MX (1) MX2020009763A (ru)
PH (1) PH12020551497A1 (ru)
PL (1) PL3770162T3 (ru)
PT (1) PT3770162T (ru)
SG (1) SG11202007979UA (ru)
TW (1) TW201941774A (ru)
WO (1) WO2019181939A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6733072B2 (ja) * 2018-03-20 2020-07-29 大日本住友製薬株式会社 ジヒドロクロメン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045707A1 (en) * 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20090111805A1 (en) * 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
KR20080054417A (ko) 2005-09-27 2008-06-17 노파르티스 아게 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
DK3050566T3 (en) * 2007-09-10 2019-03-11 Boston Biomedical Inc NEW GROUP OF STAT3 PATHWAY INHIBITORS AND CANCERCELLE-PATHWAY INHIBITORS
CN107922348A (zh) * 2015-06-22 2018-04-17 大日本住友制药株式会社 双环杂环酰胺衍生物
CN107922386B (zh) * 2015-06-22 2021-04-02 大日本住友制药株式会社 1,4-二取代的咪唑衍生物
WO2017146128A1 (ja) * 2016-02-26 2017-08-31 大日本住友製薬株式会社 イミダゾリルアミド誘導体
WO2018075959A1 (en) * 2016-10-20 2018-04-26 Forma Therapeutics, Inc. Methods using hdac11 inhibitors
JP6733072B2 (ja) * 2018-03-20 2020-07-29 大日本住友製薬株式会社 ジヒドロクロメン誘導体
JP2020019752A (ja) * 2018-08-03 2020-02-06 大日本住友製薬株式会社 クロマン誘導体

Also Published As

Publication number Publication date
US20230219970A1 (en) 2023-07-13
US20210002290A1 (en) 2021-01-07
EP3770162B1 (en) 2023-03-15
SG11202007979UA (en) 2020-09-29
PH12020551497A1 (en) 2021-09-01
CN111886237A (zh) 2020-11-03
JP2023075288A (ja) 2023-05-30
JPWO2019181939A1 (ja) 2020-06-18
BR112020017481A8 (pt) 2022-12-06
JP7247144B2 (ja) 2023-03-28
CY1126034T1 (el) 2023-11-15
TW201941774A (zh) 2019-11-01
US11639357B2 (en) 2023-05-02
AU2019239481A1 (en) 2020-09-10
HUE062256T2 (hu) 2023-10-28
AU2019239481B2 (en) 2022-11-24
WO2019181939A1 (ja) 2019-09-26
EP3770162A1 (en) 2021-01-27
BR112020017481A2 (pt) 2020-12-22
JP2020180140A (ja) 2020-11-05
US10807993B2 (en) 2020-10-20
PT3770162T (pt) 2023-03-23
US20200216461A1 (en) 2020-07-09
MX2020009763A (es) 2020-10-08
JP6733072B2 (ja) 2020-07-29
EP3770162A4 (en) 2021-12-01
DK3770162T3 (da) 2023-04-24
KR20200135401A (ko) 2020-12-02
FI3770162T3 (fi) 2023-06-02
PL3770162T3 (pl) 2023-06-05
CA3092255A1 (en) 2019-09-26
ES2941771T3 (es) 2023-05-25

Similar Documents

Publication Publication Date Title
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CY1123991T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1119473T1 (el) 1-υδροξυ-βενζοοξαβορολια ως αντιπαρασιτικοι παραγοντες
CY1119844T1 (el) 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX354021B (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
WO2014152389A8 (en) Imaging agent for detection of diseased cells
CY1114500T1 (el) Γεφυρωμενα παραγωγα σπειρο[2.4]επτανιου ως αγωνιστες υποδοχεων alx kai/ή fprl2
IL204437A (en) History of aryl cyclic profile and their use
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
NZ708909A (en) Substituted reverse pyrimidine bmi-1 inhibitors
PH12016500480B1 (en) Antibacterial 2h-indazole derivatives
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
PH12016501699A1 (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
EA201100296A1 (ru) Новые фениламино-изоникотинамидные соединения
AR084172A1 (es) Derivados aminotriazol hidroxilados como agonistas del receptor alx
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
CY1126034T1 (el) Παραγωγα διυδροχρωμενιου
MX2019001979A (es) Agonista de ppar? para el tratamiento de neoplasias hematicas.
EA200901375A1 (ru) Производные пиридазина, пиридина и пирана в качестве агонистов рецептора gpbar1
MX2013001150A (es) Marcadores de peso molecular de acetato glatiramero.